- Home
- HDL vs COLL Comparison
HDL vs COLL Comparison
Compare HDL & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HDL
- COLL
- Stock Information
- Founded
- HDL 2016
- COLL 2002
- Country
- HDL Singapore
- COLL United States
- Employees
- HDL N/A
- COLL N/A
- Industry
- HDL Restaurants
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- HDL Consumer Discretionary
- COLL Health Care
- Exchange
- HDL Nasdaq
- COLL Nasdaq
- Market Cap
- HDL 959.6M
- COLL 1.1B
- IPO Year
- HDL 2024
- COLL 2015
- Fundamental
- Price
- HDL $16.02
- COLL $29.58
- Analyst Decision
- HDL
- COLL Strong Buy
- Analyst Count
- HDL 0
- COLL 6
- Target Price
- HDL N/A
- COLL $42.00
- AVG Volume (30 Days)
- HDL 20.6K
- COLL 440.1K
- Earning Date
- HDL 11-25-2024
- COLL 11-07-2024
- Dividend Yield
- HDL N/A
- COLL N/A
- EPS Growth
- HDL N/A
- COLL 757.11
- EPS
- HDL 0.03
- COLL 2.16
- Revenue
- HDL $734,530,000.00
- COLL $599,245,000.00
- Revenue This Year
- HDL $19.69
- COLL $13.02
- Revenue Next Year
- HDL $14.20
- COLL $18.01
- P/E Ratio
- HDL $60.80
- COLL $13.68
- Revenue Growth
- HDL 15.00
- COLL 9.62
- 52 Week Low
- HDL $13.94
- COLL $25.07
- 52 Week High
- HDL $30.00
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- HDL N/A
- COLL 26.96
- Support Level
- HDL N/A
- COLL $29.69
- Resistance Level
- HDL N/A
- COLL $35.62
- Average True Range (ATR)
- HDL 0.00
- COLL 1.41
- MACD
- HDL 0.00
- COLL -0.39
- Stochastic Oscillator
- HDL 0.00
- COLL 6.36
About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.